AcquisitionsJul 29, 2026, 04:09 PM
MIMEDX to Acquire Sanara MedTech for $350M; Q2 Net Sales $64M
AI Summary
MIMEDX Group, Inc. announced plans to acquire Sanara MedTech for an enterprise value of approximately $350 million, with Sanara shareholders receiving $33.00 in cash and 0.4735 shares of MIMEDX common stock per share. Concurrently, MIMEDX reported its second quarter 2026 financial results, with net sales decreasing 35% year-over-year to $64 million, primarily due to a 61% decline in Wound sales impacted by Medicare reimbursement changes. Despite a 15% growth in Surgical product sales, the company posted a net loss of $15 million for the quarter. MIMEDX reiterated its full-year 2026 net sales guidance of $260-290 million, expecting to return to profitability in the second half of the year.
Key Highlights
- MIMEDX to acquire Sanara MedTech for $350 million enterprise value.
- Sanara shareholders to receive $33.00 cash and 0.4735 MIMEDX shares per share.
- Q2 2026 net sales were $64 million, a 35% decrease year-over-year.
- Surgical product sales increased 15% year-over-year.
- Wound sales decreased 61% year-over-year due to reimbursement changes.
- Net loss for Q2 2026 was $15 million, compared to $10 million net income in Q2 2025.
- Reiterated full-year 2026 net sales guidance of $260-290 million.
- Cash and cash equivalents stood at $136 million as of June 30, 2026.
Price Impact
More from MDXG